Muutke küpsiste eelistusi

E-raamat: Tumor Immunology and Immunotherapy

Edited by (Director and Professor of Tumour Biology, The John van Geest Cancer Research Centre, Nottingham Trent University, Nottingham, UK)
  • Formaat: PDF+DRM
  • Ilmumisaeg: 29-May-2014
  • Kirjastus: Oxford University Press
  • Keel: eng
  • ISBN-13: 9780191664557
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 178,80 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Raamatukogudele
    • Oxford Medicine Online e-raamatud
Tumor Immunology and ImmunotherapySuurem pilt
  • Formaat: PDF+DRM
  • Ilmumisaeg: 29-May-2014
  • Kirjastus: Oxford University Press
  • Keel: eng
  • ISBN-13: 9780191664557
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Patients are beginning to benefit from antibody based, cellular and vaccine approaches that are effective against genetically diverse and therapy-resistance cancers. BCG immunotherapy is now being used as a first line treatment for human bladder cancer and the introduction of prophylactic vaccination against Hepatitis B and HPV cancers is starting to show positive results. Following recent FDA approval for a vaccination against prostate cancer, and optimistic results in clinical trials for a vaccine targeting cancer antigens in lung cancer, cancer immunotherapy is now significantly impacting patient clinical management.

Tumor Immunology and Immunotherapy provides an up-to-date and comprehensive account of cancer immunity and immunotherapy. It discusses our adaptive and innate immunity to cancer, the mechanisms underpinning our immune response, current approaches to cancer immunotherapy, and how tumour and host responses can circumvent effective anti-cancer immunity.

The book examines recent results, publications and current areas of interest including 'immune editing' and the specific issues that are affecting the research and development of vaccines, providing insight into how these problems may be overcome, as viewed by world leaders in the field. Tumor Immunology and Immunotherapy will appeal to clinicians working in oncology and cancer immunotherapy, and research scientists including PhD and masters students, post-doctoral researchers and senior investigators.

Arvustused

Overall, this book provides a good overview of cancer immunotherapy with specific insights into the main clinical treatments and experimental approaches for specialists. * Doody's Notes *

1. Adaptive T-cell immunity and tumor antigen recognition ;
2. Impact of
aging and body mass on cancer immunotherapy outcomes ;
3. The potential of
natural killer cells in cancer immunotherapy ;
4. The tumour
microenvironment: the role of tumour associated macrophages in cancer
progression and responses to therapy ;
5. "Hard" and "soft" loss of MHC class
I expression in cancer cells ;
6. Modulation of the adaptive immune system
through chronic inflammation and T-regulatory responses ;
7. Myeloid-derived
suppressor cells: immune suppressive cells that facilitate tumor progression
and promote and deter cancer-associated inflammation. ;
8. Triggering death
receptors as a means of inducing tumoricidal activity ;
9. Identification of
tumor antigens for clinical evaluation ;
10. Viral antigens as targets for
prophylactic and therapeutic intervention in cancer ;
11. HER-2/neu as a
target for vaccine and antibody directed therapies ;
12. Pre-clinical
evaluation of immunotherapy: the case for prostate cancer and the tramp model
;
13. Tumor-associated antigens characterized in a conceptual framework of
biology, microenvironment, and therapy ;
14. Predictive biomarkers to better
select patients for cancer immunotherapy ;
15. Viral platforms for expression
of tumour antigens in cancer immunotherapy ;
16. Translating research into
clinical practice: lessons from the immunology and immunotherapy of
haemopoietic malignancies ;
17. DNA vaccines ;
18. Programming the immune
system through childhood infections: MUC1 Tumor Associated Antigen (TAA) as a
Disease Associated Antigen (DAA) ;
19. Vaccination against myeloid leukaemias
using newly defined antigens ;
20. Immune-checkpoint blockade in cancer
immunotherapy ;
21. Multi-peptide cancer vaccines for clinical application ;
22. Adoptive T-cell therapy using TILs for the treatment of metastatic
melanoma ;
23. Chimeric antigen receptor gene therapy in cancer ;
24. The
vaccinal effect of monoclonal antibodies in cancer therapy ;
25. Antibody
therapies: defining appropriate cell surface epitopes for targeting tumours ;
26. Adoptive lymphocyte (stem cell) therapy in cancer ;
27. Cancer Stem Cells
(CSCs) and Epithelial-to-Mesenchymal Transition (EMT): Tumor Cell Plasticity
Challenges Immunotherapy ;
28. Immune escape and aging of the immune system
compromises the immune response to tumor antigens
Lisainfo e-raamatute kohta Lisainfo e-raamatute kohta
Püsilink: https://www.kriso.ee/db/97801916645572e.html